We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
(+18%)
Cap. Flow
+$342M
Cap. Flow
% of AUM
9.57%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Avg Time Held Equity + Options
4.4
quarters
Top 10 Avg Time Held Equity + Options
5.6
quarters
Top 20 Avg Time Held Equity + Options
4.8
quarters
Avg Time Held Equity only
4.7
quarters
Top 10 Avg Time Held Equity only
5.6
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$104M |
| 2 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$79.7M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$55.2M |
| 4 |
YARW
Yarrow Bioscience
YARW
|
+$54M |
| 5 |
Amicus Therapeutics
FOLD
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$58.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$25.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$24.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$24.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.46% |
| 2 | Miscellaneous | 1.79% |
| 3 | Consumer Staples | 0.67% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.26M | 0.04% |
26,667
| – | – |
2017 Q2
3 quarters
|
|
|
VIVE
102
DELISTED
VIVEVE MED INC
VIVE
| $1.23M | 0.03% |
+335
| New | +$1.46M |
2018 Q1
0 quarters
|
|
|
PGNX
103
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.21M | 0.03% |
162,500
+100,650
| +163% | +$669K |
2017 Q4
1 quarter
|
|
|
VRNA
104
DELISTED
Verona Pharma
VRNA
| $1.12M | 0.03% |
56,168
-143,832
| -72% | -$2.08M |
2017 Q2
3 quarters
|
|
105
DELISTED
Dynavax Technologies
DVAX
| $1.11M | 0.03% |
+55,713
| New | +$962K |
2018 Q1
0 quarters
|
|
106
Sonida Senior Living
SNDA
$1.73B
| $1.08M | 0.03% |
6,678
-38,667
| -85% | -$6.87M |
2014 Q4
13 quarters
|
|
107
BeOne Medicines Ltd
ONC
$39.5B
| $958K | 0.03% |
5,700
| – | – |
2017 Q3
2 quarters
|
|
|
MRTX
108
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $893K | 0.03% |
29,091
| – | – |
2017 Q4
1 quarter
|
|
109
Protara Therapeutics
TARA
$155M
| $835K | 0.02% |
8,353
| – | – |
2014 Q4
13 quarters
|
|
|
ADYX
110
DELISTED
Adynxx Inc
ADYX
| $821K | 0.02% |
70,566
| – | – |
2014 Q4
13 quarters
|
|
111
DELISTED
Esperion Therapeutics
ESPR
| $779K | 0.02% |
10,769
| – | – |
2017 Q3
2 quarters
|
|
112
Ferrari
RACE
$68.7B
| $747K | 0.02% |
6,200
| – | – |
2016 Q1
8 quarters
|
|
113
Enanta Pharmaceuticals
ENTA
$336M
| $739K | 0.02% |
+9,132
| New | +$703K |
2018 Q1
0 quarters
|
|
114
GridAI Technologies Corp
GRDX
$32.4M
| $714K | 0.02% |
2
| – | – |
2016 Q4
5 quarters
|
|
115
DELISTED
Array Biopharma Inc
ARRY
| $655K | 0.02% |
+40,133
| New | +$643K |
2018 Q1
0 quarters
|
|
116
Nektar Therapeutics
NKTR
$1.29B
| $644K | 0.02% |
+404
| New | +$520K |
2018 Q1
0 quarters
|
|
|
VRAY
117
DELISTED
ViewRay, Inc.
VRAY
| $643K | 0.02% |
100,000
+50,000
| +100% | +$417K |
2017 Q4
1 quarter
|
|
118
DELISTED
Cutera, Inc.
CUTR
| $602K | 0.02% |
11,981
| – | – |
2017 Q1
4 quarters
|
|
119
PUT
Geron
GERN
$771M
| $600K | 0.02% |
+600,000
| New | +$1.62M |
2018 Q1
0 quarters
|
|
|
TRHC
120
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $569K | 0.02% |
+14,663
| New | +$514K |
2018 Q1
0 quarters
|
|
121
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $475K | 0.01% |
+25,000
| New | +$534K |
2018 Q1
0 quarters
|
|
122
DELISTED
Adverum Biotechnologies
ADVM
| $469K | 0.01% |
+8,085
| New | +$503K |
2018 Q1
0 quarters
|
|
123
PUT
Immunic
IMUX
$94M
| $454K | 0.01% |
+375
| New | +$861K |
2018 Q1
0 quarters
|
|
124
Senseonics Holdings Inc
SENS
$472M
| $345K | 0.01% |
5,750
| – | – |
2017 Q3
2 quarters
|
|
125
CALL
Regeneron Pharmaceuticals
REGN
$77.5B
| $335K | 0.01% |
+50,000
| New | +$17.4M |
2018 Q1
0 quarters
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $342M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.
- Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
- Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
- Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
- Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
- Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
- Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.
Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.